MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. Our proprietary product portfolio is based on technology licensed from Roswell Park Comprehensive Cancer Center that targets survivin, a cell-survival protein that is present in most cancers and rarely detectable in normal tissue. Our therapies are designed to stimulate immune responses to control tumor growth and recurrence.
SurVaxM, our lead immunotherapeutic vaccine, demonstrated safety and tolerability in a Phase I study in people with malignant gliomas (brain tumors). SurVaxM was also evaluated in a Phase II clinical trial in adults with newly diagnosed glioblastoma, showing an increase in progression free and overall survival. A Phase I clinical trial in combination with REVLIMID® (lenalidomide) as a maintenance therapy for adults with multiple myeloma (a form of blood cancer) and a Phase I clinical trial of adults with metastatic neuroendocrine tumors (NET) are ongoing.
With a team of experienced scientists, leading clinicians and industry leaders with the support of our clinical trial collaborators, patients and investors, we are committed to pursuing the most efficient path to deliver on the promise of SurVaxM and other products to improve the lives of patients battling cancer.